Glycemic Variability of Combination Therapies in T2DM

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 178 participants.

Also called NCT07442006

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 178 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07442006
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07442006. Randomized; no masking; primary purpose treatment. Start 2025-10-29 (actual); primary completion 2027-03-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Glycemic Variability of Combination Therapies in T2DM
Condition
Type 2 Diabetes Mellitus (T2DM)
Intervention (Drug)
Empagliflozin/Metformin
Intervention (Drug)
Anagliptin
Intervention (Drug)
Metformin
Intervention (Drug)
Empagliflozin/Linagliptin
Lead sponsor
JW Pharmaceutical (class: industry)

Record details

Record id
cardio:ct-nct07442006
Content hash
43a5600a6814ebff8c2798615befc3d071877c770cb78f340b7350ab4cccefa0